Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORMD-0801 in Type 2 Diabetes Mellitus
NCT06731075Phase 3Not yet recruiting
- Sponsor
- Oramed Pharmaceuticals Inc.
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ORMD-0801 in type 2 diabetes mellitus (T2DM), sponsored by Oramed Pharmaceuticals Inc.. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ORMD-0801
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06731075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731075.